Lead Sponsor

Fudan University

Age

18 - 70 years

Sex

FEMALE

Healthy Volunteers

No

•Female between 18 and 70 years old;
•Patients with histologic proved metastatic breast cancer, unsuitable to be treated with surgery;
•ECOG (Eastern Cooperative Oncology Group) 0\~1;
•Normal functions with heart, liver,renal and bone marrow:WBC≥3.5×109/L；Hb≥90 g/L；plt≥100×109/L;
•Got ICF (Informed Consent Form) before enrollment;
•Life expectancy more than 12 weeks

•Pregnant or breast-feeding women or positive serum pregnancy test;
•Uncontrolled brain metastases. Patients with brain metastases must be locally treated and the disease must be stable for at least one month at the time of enrolling;
•Participation in any investigational drug study within 4 weeks preceding treatment start;
•Concurrent other malignancy at other sites or previous other cancer within the last 5 years, with the exception of adequately treated in situ carcinoma of cervix uteri or basal or squamous cell carcinoma of the skin or a contralateral breast cancer;
•Serious uncontrolled intercurrent infections;
•Poor compliance

Related studies

NCT06994377 · Metastatic Breast Cancer

NCT07222215 · Estrogen-receptor-positive Breast Cancer, Metastatic Breast Cancer, and more

NCT02422641 · Metastatic Breast Cancer, Leptomeningeal Disease

NCT06110793 · Metastatic Breast Cancer

NCT06525766 · Anatomic Stage IV Breast Cancer AJCC v8, Estrogen-receptor-positive Breast Cancer, and more

A Phase II Study of Abraxane Gemcitabine Combination in Patients With Metastatic Breast Cancer